BBA Capital Partners invests in leading clinical research organization for the global pharmaceutical industry – Quinta-Analytica will expand service offering and expertise while maintaining customer focus
Prague/Munich, November 30, 2021
“Quinta-Analytica is a leading independent partner for pharmaceutical companies, ensuring pharmaceutical drugs are safely and rapidly brought to those who need them. The Company’s focus on its customers, high quality, scientific excellence, and flexibility differentiates it in the market. We are excited to partner with its top management team and employees to continue to be a reliable partner to Quinta-Analytica’s customers as well as to sustainably and responsibly develop the Company to the benefit of end-consumers,” explains Felix Burgdorf, Managing Director and co-owner of BBA.
Quinta-Analytica s.r.o. provides a broad range of services including analytical testing, clinical studies, and R&D to its global customer base. Founded in 1996, Quinta-Analytica has more than 200 employees and is headquartered in Prague, Czech Republic.
Roman Grunt, CEO of Quinta-Analytica, added: “This move is another step for Quinta-Analytica and its employees on our growth path. Today we have a chance to not only keep Quinta-Analytica’s essence, but with the network and financial support of our new partner we will grow further and play a leading role in building BBA’s pharma services activities.“
About BBA: BBA Capital Partners is an owner-managed and owner-financed investment company that offers medium-sized market leaders long-term entrepreneurial capital. In the “Family Equity” philosophy, BBA combines the long-term, strategic mindset of a family company with sustainable and professional corporate development.
Quinta-Analytica s.r.o., Pražská 1486/18c, 102 00 Prague 10